Figure 5From: Potential role of miR-9 and miR-223 in recurrent ovarian cancerTaqMan® PCR validation in training cohort and FFPE cohort. The relative quantitation from TaqMan® in recurrent vs primary tumours are plotted for both cohorts.Back to article page